HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: jcp.2005.029264v1 59/4/424    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aulmann, S Articles by Sinn, H P Search for Related Content PubMed PubMed Citation Articles by Aulmann, S Articles by Sinn, H P Pubmed/NCBI databases Medline Plus Health Information Breast Cancer

c-myc Amplifications in primary breast carcinomas and their local recurrences

¹ Department of Pathology, University of Heidelberg, Heidelberg, Germany
² Department of Gynaecology and Obstetrics, University of Heidelberg

Correspondence to:
Dr S Aulmann
Department of Pathology, University of Heidelberg, Im Neuenheimer Feld 220/221, 69120 Heidelberg, Germany; sebastian_aulmann{at}med.uni-heidelberg.de Objective: To evaluate the role of c-myc oncogene amplifications in the progression of invasive breast carcinomas.

Methods: c-myc gene copy number was evaluated in a series of 49 primary breast carcinomas and the corresponding local recurrences using fluorescence in situ hybridisation.

Results: 11 of the primary carcinomas (22%) harboured c-myc amplifications; these tumours typically were hormone receptor negative and occurred in younger patients (43 v 53 years). At the time of relapse, six additional tumours had acquired a c-myc amplification. The mean recurrence-free survival was 24 months; c-myc amplified tumours relapsed significantly earlier than carcinomas without amplification (18 v 27 months). Univariate analysis showed a worse overall survival in these patients.

Conclusions: While c-myc amplifications can be observed in early stage breast cancer, especially in younger patients, they often occur later in tumour development and appear to be associated with disease progression.

Abbreviations: FISH, fluorescence in situ hybridisation; IRS, immunoreactivity scores; UICC, International Union against Cancer

Keywords: breast cancer; c-myc; fluorescence in situ hybridisation

This article has been cited by other articles:

				S M. Rodriguez-Pinilla, R. L Jones, M. B K Lambros, E. Arriola, K. Savage, M. James, S. E Pinder, and J. S Reis-Filho MYC amplification in breast cancer: a chromogenic in situ hybridisation study J. Clin. Pathol., September 1, 2007; 60(9): 1017 - 1023. [Abstract] [Full Text] [PDF]